血管活性测试的临床局限性作为血管位性心脏病患者的诊断工具
1Department of Cardiology, Minami Matsuyama Hospital, Japan.
Internal medicine (Tokyo, Japan)
|May 29, 2024
概括
血管活性测试对于诊断变异性心痛 (VA) 是有用的,但对于血管性心痛 (VSA) 可能具有有限的用途. 心脏病专家应该重新考虑其在VSA诊断中的应用,特别是对于较轻的病例.
科学领域:
- 心脏病学 心脏病学
- 诊断测试 诊断测试 诊断测试
背景情况:
- 日本循环学会的指导方针建议针对血管性心脏病 (VSA) 进行血管活性测试.
- 乙胆或爱尔贡诺文测试是风变体 (VA) 的黄金标准.
- 冠内血管活性测试在VA患者中显示了可接受的灵敏度和特异性.
研究的目的:
- 总结一下诱发试验在患有变异性胸痛 (VA) 和血管性胸痛 (VSA) 的患者中的有用性.
- 为了评估血管活性测试在不同严重程度的冠状动脉的诊断价值.
主要方法:
- 对VA和VSA的血管活性测试现有文献的审查.
- 对诱发试验的诊断标准和结果的分析.
主要成果:
- 阳性血管活性测试可能表明与VA类似的疾病状态.
- 阴性血管活性测试可能表明VSA的不那么严重的形式.
- 标准的血管活性测试对于VA诊断非常有用.
结论:
- 血管活性测试对于诊断变异性胸痛 (VA) 是至关重要的.
- 对血管性心痛 (VSA) 的血管活性测试的有用性需要重新考虑,特别是在较轻微的病例中.
- 区分VA和VSA严重程度对于适当的诊断测试选择很重要.
相关概念视频
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
489
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
489
Antihypertensive Drugs: Vasodilators
503
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
503


